Allogene Therapeutics (ALLO)
(Delayed Data from NSDQ)
$2.89 USD
+0.06 (2.12%)
Updated Jul 22, 2024 04:00 PM ET
After-Market: $2.90 +0.01 (0.35%) 4:34 PM ET
2-Buy of 5 2
F Value D Growth C Momentum F VGM
Cash flow Statements
Fiscal Year End for Allogene Therapeutics, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -327.27 | -332.63 | -257.01 | -250.22 | -184.59 |
Depreciation/Amortization & Depletion | 7.39 | 17.19 | 17.41 | 10.84 | 1.43 |
Net Change from Assets/Liabilities | -15.31 | 3.71 | -32.09 | 53.92 | -6.88 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 97.45 | 91.22 | 86.87 | 70.37 | 52.69 |
Net Cash From Operating Activities | -237.73 | -220.52 | -184.81 | -115.09 | -137.35 |
Property & Equipment | -1.52 | -5.19 | -21.45 | -65.96 | -50.79 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | 164.81 | 111.35 | 185.10 | -439.16 | 214.88 |
Other Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | 163.29 | 106.16 | 163.66 | -505.12 | 164.08 |
Uses of Funds
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 95.70 | 2.95 | 11.96 | 633.59 | 58.96 |
Issuance (Repayment) of Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Financing Activities | 95.70 | 2.95 | 11.96 | 633.59 | 58.96 |
Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | 21.25 | -111.41 | -9.19 | 13.38 | 85.69 |
Cash at Beginning of Period | 72.20 | 183.61 | 192.80 | 179.43 | 93.73 |
Cash at End of Period | 93.45 | 72.20 | 183.61 | 192.80 | 179.43 |
Diluted Net EPS | -2.09 | -2.32 | -1.89 | -2.08 | -1.83 |
Fiscal Year End for Allogene Therapeutics, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | NA | -65.00 | -327.27 | -238.01 | -176.69 |
Depreciation/Amortization & Depletion | NA | 0.76 | 7.39 | 7.21 | 6.58 |
Net Change from Assets/Liabilities | NA | -4.44 | -15.31 | -11.90 | 2.99 |
Net Cash from Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | NA | 12.78 | 97.45 | 58.67 | 38.63 |
Net Cash From Operating Activities | NA | -55.90 | -237.73 | -184.03 | -128.50 |
Property & Equipment | NA | -0.01 | -1.52 | -1.34 | -1.32 |
Acquisition/ Disposition of Subsidiaries | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | NA | 22.14 | 164.81 | 97.16 | 131.42 |
Other Investing Activities | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | NA | 22.13 | 163.29 | 95.83 | 130.10 |
Uses of Funds
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | NA | 1.65 | 95.70 | 95.54 | 91.26 |
Issuance (Repayment) of Debt | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Increase (Decrease) Short-Term Debt | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Financing Activities | NA | 1.65 | 95.70 | 95.54 | 91.26 |
Effect of Exchange Rate Changes | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | NA | -32.12 | 21.25 | 7.34 | 92.85 |
Cash at Beginning of Period | NA | 93.45 | 72.20 | 72.20 | 72.20 |
Cash at End of Period | NA | 61.33 | 93.45 | 79.54 | 165.05 |
Diluted Net EPS | NA | -0.38 | -0.51 | -0.37 | -0.53 |